Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Total Stockholders Equity : $0.61 Mil (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Cyclacel Pharmaceuticals Total Stockholders Equity?

Cyclacel Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $0.61 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Cyclacel Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was $N/A. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Cyclacel Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.06.

Cyclacel Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Cyclacel Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals Total Stockholders Equity Chart

Cyclacel Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

11.70

33.26

37.69

20.43

0.61

Cyclacel Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial															20.43	14.64	9.63	4.30	0.61

Cyclacel Pharmaceuticals (NAS:CYCCP.PFD) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Cyclacel Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(0.607	-	0)	/	0
	=	N/A

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Cyclacel Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0.037)	/	0.607
	=	0.06

Cyclacel Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (NAS:CYCCP.PFD) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

CYCC:USA UXI:Germany

Address

200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922

Website

https://www.cyclacel.com

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.